Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07.

At the 2017 Annual Meeting of Stockholders of Aerie
Pharmaceuticals, Inc. (the Company), held on June8, 2017, the
Companys stockholders (1)elected the persons listed below as
directors to serve on the Board of Directors (the Board) for a
three-year term and (2)ratified the appointment of
PricewaterhouseCoopers LLP as the Companys independent registered
public accounting firm for the fiscal year ending December31,
2017.

The table below sets forth the number of votes cast for, against
or withheld, and the number of abstentions and broker non-votes,
as applicable, for each matter voted upon by the Companys
stockholders.

The qualifications of the three candidates for director were
evaluated and considered by both the Board and the Nominating and
Corporate Governance Committee of the Board.As disclosed in the
Companys Schedule 14A 2017 Proxy Statement, the Board determined
that, in light of prior business experience and service on the
Board, each of the three candidates for director possessed the
qualifications and skills to continue serving as a member of the
Board.During the Companys fiscal year ended December31, 2016,
each of the three candidates for director attended more than
seventy-five percent (75%)of all Board meetings.In addition, each
of the three candidates for director attended more than
seventy-five percent (75%)of all meetings of the Board
committee(s) on which they served during such period, except for
Ms.McHugh, who attended four of seven meetings of the Audit
Committee of the Board (the Audit Committee).With respect to the
three meetings of the Audit Committee which Ms.McHugh did not
attend, Ms.McHugh notified Company management and the other
members of the Audit Committee of her absence in advance of each
meeting and independently reviewed and discussed with Company
management and the other members of the Audit Committee the
materials and topics covered at those meetings.

About Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan. Its product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Rhopressa is a once-daily eye drop and a triple-action netarsudil ophthalmic solution. The active ingredient in Rhopressa acts through the inhibition of both Rho Kinase (ROCK) and norepinephrine transporter (NET). Roclatan is a once-daily, quadruple-action product candidate and is a fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with glaucoma. The Company is engaged in conducting Phase III clinical trials for Rhopressa and Roclatan.